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Background: Drospirenone/ethinyl-estradiol is an oral contraceptive (OC) that possesses unique
antimineralocorticoid activity. It is conjectured that drospirenone, taken alone or concomitantly with
spironolactone, may be associated with an increased risk of hyperkalemia.
Methods: A retrospective cohort study was conducted evaluating women between 18-46 years of age in the
Lifelink™ Health Plan Claims Database. The study was restricted to new users of OCs between 1997-2009. Cox
proportional hazards models were used to estimate the time to first occurrence of hyperkalemia diagnosis. The
main analysis compared OCs containing drospirenone with OCs containing levonorgestrel, a second generation OC
not known to impact potassium homeostasis. Logistic regression evaluated concomitant prescribing of
drospirenone and spironolactone
Results: The cohort included 1,148,183 women, averaging 28.8 years of age and 280 days of OC therapy. 2325
cases of hyperkalemia were identified. The adjusted hazard ratio (HR) for hyperkalemia with drospirenone
compared to levonorgestrel was 1.10 (95%CI 0.95-1.26). There was an increased risk of hyperkalemia with
norethindrone HR 1.15 (95%CI: 1.00-1.33) and norgestimate HR 1.27 (95%CI: 1.11-1.46). Other OCs were
unassociated with hyperkalemia. The odds of receiving spironolactone while taking drospirenone were 2.66 (95%CI
2.53-2.80) times higher than the odds of receiving spironolactone and levonorgestrel. Only 6.5% of patients taking
drospirenone and spironolactone had a serum potassium assay within 180 days of starting concomitant therapy.
Conclusions: A clinically significant signal for hyperkalemia with drospirenone was not demonstrated in the
current study. Despite the bolded warning for hyperkalemia with joint drospirenone and spironolactone
administration, physicians are actually using them together preferentially, and are not following the recommended
potassium monitoring requirements in the package insert.
Background
Drospirenone is a novel synthetic progestin approved in
combination with ethinyl estradiol as an oral contraceptive
(OC) [1]. Marketed as Yasmin
® and Yaz
®, drospirenone is
one of the most popular oral contraceptives in the United
States [2]. Drospirenone is a fourth generation OC and it
possesses antimineralocorticoid effects not present in pre-
vious generations of OCs. Its antimineralocorticoid
potency is approximately eight times greater than spirono-
lactone [3], thus a 3 mg tablet of drospirenone has a simi-
lar effect to 20-25 mg of spironolactone [4]. This activity
enhances sodium, chloride, and water excretion, while
reducing the excretion of potassium, ammonium, and
phosphate [5]. The similarity in chemical structure
between drospirenone and spironolactone and the known
association between spironolactone and hyperkalemia
both strengthen the plausibility that clinically significant
hyperkalemia might result from drospirenone use.
In May of 2001, when drospirenone/ethinyl estradiol
(Yasmin
®) was first approved, the package insert
included a bolded warning for hyperkalemia, stating that
“Yasmin should not be used in patients with conditions
that predispose to hyperkalemia” [1]. The warning also
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the first cycle of treatment in patients taking concomitant
medications known to cause hyperkalemia. Clinical evi-
dence however has not shown a strong association
between drospirenone and hyperkalemia [6-13]. Several
studies have evaluated for hyperkalemia in postmenopau-
sal women with hypertension or diabetes who use dros-
pirenone to treat vasomotor spasms. These studies found
no association between drospirenone and hyperkalemia
in women with hypertension [6,7] or type 2 diabetes mel-
litus [8]; however, all three studies were twelve or fewer
weeks in duration. Larger trials designed to evaluate the
safety and efficacy of drospirenone either do not evaluate
hyperkalemia or are not powered to detect it [9-12]. Only
one large study, mandated by the FDA at approval, has
been performed evaluating drospirenone for hyperkale-
mia in younger women, and it found no association
between drospirenone and hyperkalemia [13].
Hyperkalemia is a potentially serious condition that
may be associated with numerous pathophysiological
conditions. Clinically significant hyperkalemia reduces
membrane excitability and disturbs the acid-base bal-
ance, manifesting as weakness, flaccid paralysis, hypo-
ventilation, and metabolic acidosis. Hyperkalemia can
also result in cardiac toxicity with electrocardiographic
changes, which in severe cases may lead to the terminal
events of ventricular fibrillation or asystole [5].
The primary objective of the current study is to inves-
tigate the association between drospirenone and the
diagnosis of hyperkalemia in a large unselected popula-
tion. A secondary objective is to evaluate the impact of
the package insert on medical prescribing as assessed by
an examination of the 1) concomitant use of drospire-




The IMS Lifelink™ Health Plan Claims Database con-
tains paid claims data from over 102 managed care
plans in the United States. The database contains fully
adjudicated medical and pharmacy claims for over 68
million patients, including inpatient and outpatient diag-
noses and procedures (International Classification of
Diseases, 9
th Revision, Clinical Modification format)i n
addition to retail and mail order prescription records.
The data is representative of US residents with private
health insurance in terms of geography, age, and gender.
The Lifelink™ database is subject to quality checks to
ensure data quality and to minimize error rates [14].
Cohort description
A retrospective cohort was developed, evaluating women
in the Lifelink™ Claims database between January 1
st,
1997 and December 31
st, 2009. All women between 18-
46 years of age with the first prescription for an OC
containing ethinyl estradiol (0.35 ug or less) and one of
the following progestins were included in the cohort:
desogestrel, drospirenone, ethynodiol diacetate, levonor-
gestrel, norethindrone acetate, norethindrone, norgesti-
mate, and norgestrel. All patients who met these
inclusion criteria were analyzed in the utilization portion
of the study.
For the hyperkalemia analysis, in order to include only
new users, patients were excluded if they did not have
at least 180 days of enrollment history prior to their
first claim for an OC. Patients were also excluded if
they had a prior diagnosis of hyperkalemia. Censoring
was performed if a patient switched to another OC dur-
ing the study period, on the final day of OC possession
(determined from the final prescription date and day
supply), before a gap in OC possession of 30 or more
days, at the event of hyperkalemia, and at the end of the
study period, December 31
st, 2009. Evaluation of hyper-




Cox proportional hazard models were used to estimate
the time to first occurrence of hyperkalemia. The pri-
mary analysis used a new user design and compared
OCs containing drospirenone with OCs containing levo-
norgestrel. Levonorgestrel was chosen ap r i o r ias a
reference based on its high utilization, lack of associa-
tion with hyperkalemia, and use as a reference in pre-
vious OC comparative-safety studies [15-21]. All
estimates were adjusted by age, calendar time, chronic
kidney disease, diabetes mellitus, hypertension, inflam-
matory bowel disease, obesity [22], polycystic ovary syn-
drome, premenstrual tension syndrome (premenstrual
syndrome and premenstrual dysphoric disorder), smok-
ing status, and concomitant medications known to
cause hyperkalemia. The following medications were
adjusted for: angiotensin-converting enzyme inhibitors
(ACE)/angiotensin receptor blockers (ARB), non-steroi-
dal anti-inflammatory drugs (NSAID), spironolactone,
and other medications (cyclosporine, diuretics, heparin,
penicillin G, tacrolimus, and trimethoprim).
Utilization
Concomitant utilization of drospirenone and spironolac-
tone was analyzed during the entire study period. Logis-
tic regression was used to form odds ratios (OR)
comparing the odds for receiving concomitant spirono-
lactone and drospirenone therapy against the odds of
receiving concomitant spironolactone and levonorgestrel
therapy. ORs were also formed calculating the odds of
receiving spironolactone while on other progestin-
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compliance with potassium monitoring for patients tak-
ing concomitant drospirenone and spironolactone, the
percentage of patients who had a blood serum potas-
sium assay (CPT-4 84132) during the first 180 days of
concomitant therapy was calculated.
This study was approved by the University of Florida




The cohort included 1,148,183 women exposed to a pro-
gestin-based OC and 880,014 person-years of follow-up
time. Patients in the study averaged 28.8 years of age and
had a mean follow up time of 280 days. There were 2325
cases of hyperkalemia, representing 0.20% of the popula-
tion. Baseline characteristics are shown in Table 1.
The adjusted hazard ratio (HR) for a recorded diagno-
sis of hyperkalemia while exposed to drospirenone com-
pared to levonorgestrel was 1.10 (95% CI 0.95-1.26).
Other OCs were unassociated with hyperkalemia: deso-
gestrel HR 1.00 (95%CI: 0.85-1.17), ethynodiol diacetate
HR 0.71 (95%CI: 0.49-1.02), norethindrone acetate HR
1.08 (95%CI: 0.91-1.29), norgestrel HR 1.00 (95%CI:
0.76-1.33), although there was an unexpected signal
with norethindrone HR 1.15 (95%CI: 1.00-1.33) and nor-
gestimate HR 1.27 (95%CI: 1.11-1.46) (Table 2). Addi-
tionally, the analysis found no interaction between
drospirenone and spironolactone for hyperkalemia in
the regression model (HR 1.08, 95%CI: 0.78-1.49). Other
interactions with drospirenone in the regression model
were as follows: ACEI/ARB HR 0.78 (95%CI 0.55-1.10)
and NSAID HR 1.09 (95%CI 0.80-1.48).
Utilization
The utilization study evaluated all 2,925,407 patients
that met the initial study inclusion criteria. 18,869
patients in this population were taking both spironolac-
tone and an OC. The odds of receiving spironolactone
while on drospirenone were 2.66 (95%CI 2.53-2.80)
times higher than the odds of receiving spironolactone
while on levonorgestrel. The ORs for receiving spirono-
lactone while on other progestin-based OCs compared
to levonorgestrel are as follows: desogestrel 1.46 (95%CI
1.38-1.55), ethynodiol diacetate 2.85 (95%CI 2.62-3.11),







Number of patients 139,871 224,408 17,295 180,720 93,818 234,105 228,276 29,690
Age 28.7 29.0 28.8 29.0 30.5 29.7 26.9 29.7
Mean follow up
(days)
327 272 327 304 240 230 307 249
Number of cases 267 488 33 349 200 433 499 56
Covariates (%)
CKD † 0.15 0.09 0.08 0.09 0.12 0.15 0.08 0.19
Diabetes 4.10 4.10 4.41 3.93 4.13 4.12 3.37 5.43
Hypertension 8.34 8.47 8.53 8.62 9.78 8.89 6.55 10.82
IBD* 0.94 1.03 1.22 1.00 1.03 0.85 0.75 0.98
Obesity 11.59 12.53 12.44 11.22 10.75 10.08 9.50 13.60
PCOS ᶋ 4.47 5.78 5.00 2.11 2.80 2.81 2.21 3.48
PTS (PMS/
PMDD) ‡
3.63 5.53 3.04 3.01 3.26 1.95 1.69 2.73
Smoking 6.62 5.94 8.48 7.36 6.43 6.49 6.97 9.00
ACEI/ARB § 0.50 0.47 0.56 0.60 0.75 0.67 0.42 0.80
NSAIDS ʗ 5.67 4.84 5.79 5.56 5.13 5.90 4.77 6.09
Spironolactone 0.43 0.74 0.84 0.28 0.32 0.19 0.32 0.29
Other
Medications ʒ
0.46 0.36 0.56 0.46 0.37 0.35 0.27 0.44
*Inflammatory bowel disease
† CKD = Chronic Kidney Disease
ᶋ PCOS = Polycystic Ovary Syndrome
‡ PTS (PMS/PMDD) = premenstrual tension syndrome (premenstrual syndrome and premenstrual dysphoric disorder)
§ ACE/ARB = angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
ʗ NSAID = non-steroidal anti-inflammatory drugs
ʒ Other medications = diuretics, heparin, cyclosporine, tacrolimus, trimethoprim, and penicillin G
Bird et al. BMC Clinical Pharmacology 2011, 11:23
http://www.biomedcentral.com/1472-6904/11/23
Page 3 of 6norethindrone acetate 1.01 (95%CI 0.93-1.08), norethin-
drone 0.78 (95%CI 0.74-0.83), norgestimate 1.34 (95%CI
1.27-1.41), and norgestrel 0.98 (95%CI 0.89-1.08). The
Yasmin
® and Yaz
® package inserts recommend potas-
sium monitoring within the first treatment cycle for
patient taking other medications known to cause hyper-
kalemia. Of the 5,752 patients who took drospirenone
and spironolactone concomitantly, only 376 (6.5%)
patients underwent a serum potassium assay within 180
days of starting concomitant therapy.
Discussion
The current study did not find a substantial and mean-
ingful association between drospirenone use and hyper-
kalemia compared to patients taking levonorgestrel. It is
interesting to note that norethindrone and norgestimate
are both associated with a higher risk for hyperkalemia
compared to levonorgestrel. These however were not a
priori hypotheses and may be chance findings due to
multiple testing. These results must also be taken into
context with the low absolute risk for hyperkalemia in
OC users. The increased HR for norethindrone of 1.16
results in a number need to harm (NNH) of 3086
patients, while the HR for norgestimate of 1.27 results
in a NNH of 1829 patients.
The null association between drospirenone and hyper-
kalemia is concordant with the results from previous
studies [13,23]. To our knowledge, only one prior cohort
study has been conducted with the primary aim to eval-
uate drospirenone and hyperkalemia [13]. This study
had 67,287 OC users, identified 378 cases of hyperkale-
mia, and found a RR comparing drospirenone to other
OCs of 0.9 (95%CI 0.7-1.1). Our study population has
approximately seventeen times the OC user population
of this prior analysis, allowing greater detection for
hyperkalemia and providing increased statistical preci-
sion. Another study identified 102 cases of drug-asso-
ciated hyperkalemia and did not attribute any cases to
use of drospirenone [23]. In our study, the comparison
among OC users in our analysis minimizes the risk of
confounding by indication, and the new user design
eliminates the survivor effect that long term OC users
are tolerant to the therapy and healthier than short
term users. The totality of the evidence suggests that
hyperkalemia while on drospirenone is not of clinical
importance.
Utilization
We found that drospirenone users are 2.66 times more
likely to receive spironolactone compared with levonor-
gestrel users. An OR of this magnitude suggests that
physicians are not avoiding the concomitant use of dros-
pirenone and spironolactone, but prescribing them
together. This is a particularly interesting finding
because drospirenone is the only OC with a bolded
warning for hyperkalemia. These medications have no
overlap in labeled indications; however, drospirenone
does have an indication for acne vulgaris, while spirono-
lactone has an off-label use for its treatment. Another
likely explanation in the recent literature is that drospir-
enone and spironolactone are both seen as beneficial for
treatment of weight gain and bloating experienced by
patients with postmenstrual dysphoric disorder and in
reducing hirsutism and acne in patients with polycystic
ovarian syndrome (PCOS) [24-28].
It was recently reported that, among 11,019 drospire-
none users, 17.6% of patients are taking another medica-
tion known to induce hyperkalemia [29]. In this study,
spironolactone accounted for 11.1% of this concomitant
utilization. Our study found that only 6.5% of patients
taking drospirenone and spironolactone underwent
potassium monitoring. This raises concern that few phy-
sicians are following the recommendations for monitor-
ing serum potassium as stated in the package insert.
Although we found a non-significant interaction for
hyperkalemia with concomitant use of drospirenone and
spironolactone, this does not assure the safe combined
use of these two medications. Particularly, patients with
PCOS generally express characteristics of metabolic syn-
drome, are at an increased risk for drug induced liver
injury [30], and warrant careful monitoring.
Limitations
The use of ICD-9-CM codes for the detection of hyper-
kalemia provides a high specificity for diagnosed cases
because this diagnosis is made from an assay of serum
potassium. This measurement however lacks sensitivity
due to a lack of potassium testing in the general popula-
tion. Inadequacies in documenting ICD-9-CM codes
Table 2 Risk for hyperkalemia* with use of commonly
used oral contraceptives
Crude HR (95% CI) Adjusted HR† (95%CI)
Levonorgestrel 1.0 (reference) 1.0
Desogestrel 0.93 (0.79-1.09) 1.00 (0.85-1.17)
Drospirenone 1.26 (1.10-1.44) 1.10 (0.95-1.26)
Ethynodiol diacetate 0.96 (0.67-1.38) 0.71 (0.49-1.02)
Norethindrone acetate 1.41 (1.18-1.68) 1.08 (0.91-1.29)
Norethindrone 1.27 (1.11-1.47) 1.15 (1.00-1.33)
Norgestimate 1.13 (0.98-1.29) 1.27 (1.11-1.46)
Norgestrel 1.13 (0.85-1.49) 1.00 (0.76-1.33)
*Hyperkalemia determined from a diagnostic ICD-9 code (276.7)
† Adjusted by age, calendar time, chronic kidney disease, diabetes mellitus,
hypertension, inflammatory bowel disease, obesity, polycystic ovary syndrome,
premenstrual tension syndrome (premenstrual syndrome and premenstrual
dysphoric disorder), smoking status, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers, non-steroidal anti-inflammatory
drugs, spironolactone, and other medications known to cause hyperkalemia
(cyclosporine, diuretics, heparin, penicillin G, tacrolimus, and trimethoprim).
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determine if this was likely to be problematic, we inter-
rogated the Lifelink™ database to investigate control
drugs with known associations to hyperkalemia. Amilor-
ide, a potassium-sparing diuretic, spironolactone, an
aldosterone antagonist, and all ACE inhibitors were
selected as positive controls. The Lifelink™ database
was able to replicate three known positive associations:
amiloride HR 7.94 (95%CI 1.96-32.08), spironolactone
HR 3.46 (95%CI 2.97-4.02), and ACE inhibitors HR 1.90
(95%CI 1.70-2.11). Negative controls selected were lora-
tadine, a non-drowsy antihistamine, topical hydrocorti-
sone, and all statins. All negative associations were
replicated: loratadine HR 0.84 (95%CI 0.60-1.20), topical
hydrocortisone HR 1.37 (95%CI 0.92-2.05), and statins
HR 1.06 (95%CI 0.92-1.22). A positive association was
not found between NSAIDS and hyperkalemia (HR 0.93
(95%CI 0.81-1.06)). The above positive and negative
controls are reassuring for the ability of this claims data-
base to detect clinically relevant hyperkalemia and to
find a null result when no association is known.
The bolded warning for drospirenone and hyperkale-
mia also has the potential to introduce a measurement
bias. This warning makes potassium monitoring in the
drospirenone group more likely, inducing a bias away
from the null. This anti-conservative bias provides addi-
tional confidence in our null result. If channeling bias is
present in our study population, steering patients at
high risk for hyperkalemia away from drospirenone
would provide a bias toward the null. Another interpre-
tation of the study results is that, based on the regula-
tory framework, current clinical practice is sufficient to
mitigate the risk of hyperkalemia in this population.
Due to the nature of a claims database, residual con-
founding is always present. Alcohol consumption, ethni-
city, and diet are all potential unadjusted confounders in
our study. Two covariates in the analysis, smoking and
obesity, are reported only to justify treatment (such as
bariatric surgery or smoking cessation therapy) and are
not completely controlled.
Future implications
Although a clinically significant increase in the diagno-
sis of hyperkalemia was not found in our analysis, a
subclinical increase in serum potassium in this popula-
tion cannot be ruled out. Increased utilization of spiro-
nolactone in patients taking drospirenone and poor
compliance with the requirement for potassium moni-
toring in the package insert suggests a lack of attention
to the possibility of hyperkalemia. Spironolactone how-
ever has a strong association with hyperkalemia, and,
for patients taking both spironolactone and drospire-
none, it is concerning that so few physicians follow the
package insert monitoring recommendations. This
suggests that package inserts may not be an effective
mechanism for the communication of drug safety
information. If an increase in hyperkalemia had been
found in patients taking drospirenone, this current
monitoring practice may not have been sufficient to
detect it.
Conclusions
In a large cohort of young women, drospirenone did not
cause a clinically significant increase in risk for hyperka-
lemia when compared with other progestin-containing
OCs. It is however concerning that, despite the bolded
warning for hyperkalemia, drospirenone and spironolac-
tone are used together preferentially. This likely demon-
strates a channeling of patients with premenstrual
dysphoric disorder and polycystic ovary syndrome to
use of drospirenone. Furthermore, physicians are not
following the monitoring requirements for serum potas-
sium assays in the package insert for patients taking
these two medications.
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